Key facts
- Courage Therapeutics’s last known valuation is $11.0M (Apr 2025).
- It has raised $8.8M across 1 recorded rounds; the latest was Seed Round ($4.5M) in Apr 2025.
- Notable investors include What If Ventures, Innovation Partnerships, Arsenal Bridge Ventures, Michigan Biomedical Venture Fund, NASA SBIR/STTR — 6 tracked in total.
- Courage Therapeutics has filed 1 Form D with the SEC, most recently May 2025 ($4.5M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Courage Therapeutics
Funding rounds
1 roundsAbout Courage Therapeutics
Developer of obesity treatment drugs designed to treat anorexia nervosa and obesity. The company uses patents relating to the composition of matter and activity to sensitize patients to anorexigenic medicines and help to treat increased feeding behavior in mouse models of feeding, enabling physicians to get access to drugs in areas of unmet medical need.
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2019
- Employees
- 4
- Website
- couragetx.com/
- Ownership
- Privately Held (backing)
Courage Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Courage Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Courage Therapeutics in its N-PORT filings yet. We sweep new filings monthly.